Medical Oncology

, Volume 28, Supplement 1, pp 644–646 | Cite as

Activity of trabectidin in desmoplastic small round cell tumor

  • Ana López-González
  • Blanca Cantos
  • Eva Tejerina
  • Mariano ProvencioEmail author


Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive cancer that typically arises in teenage boys. As a result of its low prevalence, there have been few studies of its treatment and impact on survival. Here, we report the case of a patient who was refractory to multiple drugs but remains stable with trabectedin. To our knowledge, this is the first published report that supports antitumoral activity of trabectedin in DSRCT.


Desmoplastic small round cell tumor EWT/WT1 fusion transcript Trabectidin 


  1. 1.
    Stuart-Buttle CE, Smart CJ, Pritchard S, Martin D, Welch IM. Desmoplastic small round cell tumour: a review of literature and treatment options. Surg Oncol. 2008;17(2):107–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Tejerina González E, Corbacho Cuevas C, López García A, Bellas C, Sánchez V, Sánchez Ruiz A, de Álava E, Sanz E. Tumor intraabdominal desmoplásico de células pequeñas y redondas. Revisión de la literatura a propósito de un caso con estudio citológico, histopatológico, inmunohistoquímico y molecular. Oncología. 2007;30(1):25–31.Google Scholar
  3. 3.
    Landayi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumors. Cancer Res. 1994;54:2837–40.Google Scholar
  4. 4.
    Hassan I, et al. Intraabdominal desmoplastic small round cell tumours—a diagnostic and therapeutic challenge. Cancer. 2005;104(6):1264–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Livaditi E, Mavridis G, Soutis M, et al. Diffuse intraabdominal desmoplastic small round cell tumour: a ten-year experience. Eur J Pediatr Surg. 2006;16(6):423–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Herrero AB, Martín-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66(16):8155–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Grosso F, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595–602.PubMedCrossRefGoogle Scholar
  8. 8.
    Grosso F, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009;20(8):1439–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Bonfanti M, La Valle E, Fernández Sousa-Faro JM, Faircloth G, Caretti G, Mantonvani R, D’Incalci M. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 1999;14:179–86.PubMedGoogle Scholar
  10. 10.
    Forni C, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8(2):449–57.PubMedCrossRefGoogle Scholar
  11. 11.
    Tavecchio M, et al. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif. 2007;40:885–904.PubMedCrossRefGoogle Scholar
  12. 12.
    Tavecchio M, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer. 2008;44:609–18.PubMedCrossRefGoogle Scholar
  13. 13.
    Soares DG, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. PNAS. 2007;104(32):13062–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Ana López-González
    • 1
  • Blanca Cantos
    • 1
  • Eva Tejerina
    • 2
  • Mariano Provencio
    • 1
    Email author
  1. 1.Medical OncologyHospital Universitario Puerta de HierroMadridSpain
  2. 2.Pathology AnatomyHospital Universitario Puerta de HierroMadridSpain

Personalised recommendations